These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 27644404

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M, Krupka-Matuszczyk I.
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [Abstract] [Full Text] [Related]

  • 4. Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers.
    Stassinos G, Klein-Schwartz W.
    Clin Toxicol (Phila); 2018 May; 56(5):355-359. PubMed ID: 28992737
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of lisdexamfetamine and dextroamphetamine exposures reported to U.S. poison centers.
    Kaland ME, Klein-Schwartz W.
    Clin Toxicol (Phila); 2015 Jun; 53(5):477-85. PubMed ID: 25832473
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Overdoses and ingestions of second-generation antipsychotics in children and adolescents.
    Antia SX, Sholevar EH, Baron DA.
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):970-85. PubMed ID: 16379518
    [Abstract] [Full Text] [Related]

  • 11. Characterization of edible marijuana product exposures reported to United States poison centers.
    Cao D, Srisuma S, Bronstein AC, Hoyte CO.
    Clin Toxicol (Phila); 2016 Nov; 54(9):840-846. PubMed ID: 27418198
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Aripiprazole exposures reported to Texas poison control centers during 2002-2004.
    Forrester MB.
    J Toxicol Environ Health A; 2006 Sep; 69(18):1719-26. PubMed ID: 16864422
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Medical care costs and hospitalization in patients with bipolar disorder treated with atypical antipsychotics.
    Bergeson JG, Kalsekar I, Jing Y, You M, Forbes RA, Hebden T.
    Am Health Drug Benefits; 2012 Sep; 5(6):379-86. PubMed ID: 24991334
    [Abstract] [Full Text] [Related]

  • 16. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
    Citrome L, Kalsekar I, Guo Z, Laubmeier K, Hebden T.
    Clin Ther; 2013 Dec; 35(12):1867-75. PubMed ID: 24119767
    [Abstract] [Full Text] [Related]

  • 17. Prospective observational multi-poison center study of ziprasidone exposures.
    Klein-Schwartz W, Lofton AL, Benson BE, Spiller HA, Crouch BI.
    Clin Toxicol (Phila); 2007 Dec; 45(7):782-6. PubMed ID: 17926152
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR.
    J Am Pharm Assoc (2003); 2007 Dec; 47(3):373-8. PubMed ID: 17510032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.